Otsuka Pharmaceutical Co. Ltd.’s topical candidate for atopic dermatitis (AD) has met its endpoints in a Japanese Phase III program, setting the stage for an approval filing in this potentially large market.
Two double-blind, parallel-group studies with the phosphodiesterase 4 (PDE4) inhibitor difamilast (OPA-15406) in both adult and pediatric patients assessed 1%...







